Population	2012
------------	------

## 1.1 million

		Rate
Estimates of TB burden * 2012	Number (thousands)	(per 100 000 population)
Mortality (excludes HIV+TB)	0.82 (0.36–1.5)	74 (33–132)
Mortality (HIV+TB only)		
Prevalence (includes HIV+TB)	8.4 (3.8–15)	758 (342–1 335)
Incidence (includes HIV+TB)	5.6 (4.6–6.6)	498 (409–596)
Incidence (HIV+TB only)		
Case detection, all forms (%)	69 (58–84)	

Total new	3 788		Total retreatment	49	
Other	0	(0)			
Extrapulmonary	420	(11)	Other		
Smear-unknown / not done	0	(0)	Treatment after default	5	(10)
Smear-negative	1 823	(48)	Treatment after failure	4	(8)
Smear-positive	1 545	(41)	Relapse	40	(82)
New cases		(%)	Retreatment cases		(%)
TB case notifications 2012					

## Other (history unknown)

Total new and relapse	3 828	Total cases notified	3 837

New cases	Smear-positive	Smear-negative/ unknown/ not done	Extrapulmonary
M:F ratio	1.3	1.2	0.8
Age < 15	19	334	118

Laboratories	2012
Smear (per 100 000 population)	1.6
Culture (per 5 million population)	
Drug susceptibility testing (per 5 million population)	
Is second-line drug susceptibility testing available?	No


Treatment success rate 2011 (%)			
New smear-positive and/or culture-positive	91	Is rifampicin used	
New smear-negative/extrapulmonary		throughout treatment for	
Retreatment	77	new patients?	No


TB/HIV 2012	Number	(%)
TB patients with known HIV status	766	(20)
HIV-positive TB patients	4	(<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)		
HIV-positive TB patients on antiretroviral therapy (ART)	4	(100)
HIV-positive people screened for TB		
HIV-positive people provided with IPT		


Estimates of MDR-TB burden 2012*	New	Retreatment
% of TB cases with MDR-TB	2.2 (1.6–2.8)	16 (11–21)
MDR-TB cases among notified pulmonary TB cases	74 (54–94)	8 (5–10)


Reported cases of MDR-TB 2012	New	Retreatment	Total
Cases tested for MDR-TB		3 (6%)	3
Laboratory-confirmed MDR-TB cases		3	3
Patients started on MDR-TB treatment			4

Financing TB control	2013
National TB programme budget (US\$ millions)	1.7
% Funded domestically	7%
% Funded internationally	93%
% Unfunded	0%










\_\_\_ New smear-positive and/or culture-positive \_\_\_ New smear-negative/extrapulmonary \_\_\_ Retreatment



\_\_\_ HIV-positive TB patients \_\_\_ on CPT \_\_on ART

## Total budget (US\$ millions)

